acute myeloid leukemia – Page 2

Decoding Chromosome 5q Deletion: Driving Aneuploidy Evolution and Therapeutic Strategies in Complex Karyotype Myeloid Neoplasms

By MedXY 09/01/2026

Chromosome 5q deletions combined with TP53 mutations drive stepwise aneuploid evolution in complex karyotype AML, unveiling shared transcriptional vulnerabilities exploitable by targeted therapies like BCL2 inhibition with venetoclax.

Hematology-Oncology news Pathology & Lab Medicine

Enhancing Prognostic Accuracy in Acute Myeloid Leukemia through DNA Methylation Signatures

By MedXY 08/28/2026

DNA methylation profiling in AML patients reveals epigenetic subtypes that mirror genetic mutations, improving risk stratification and outcome prediction beyond standard genetic markers.

Hematology-Oncology news

Comparative Outcomes of Treosulfan- versus Busulfan-Based Clofarabine Reduced Intensity Conditioning Regimens in Adult Allogeneic Transplant for Myeloid Malignancies

By MedXY 08/25/2026

This retrospective study compares treosulfan and busulfan combined with clofarabine as reduced intensity conditioning before allogeneic transplant in adults with myeloid malignancies, highlighting faster neutrophil recovery and improved survival metrics with treosulfan.

Hematology-Oncology news Oncology

Dual HLA-Restricted TCR-Engineered T Cells Targeting Cathepsin G: A Novel Approach for Effective AML Eradication

By MedXY 08/25/2026

This study demonstrates that T cells engineered with a dual HLA-restricted TCR against cathepsin G effectively and safely eradicate AML cells, offering a promising immunotherapy for a broad AML patient population.

$Enhanced Salvage Therapy in Relapsed/Refractory AML: Venetoclax Plus High-Dose Cytarabine and Mitoxantrone Shows Promising Outcomes and Risk Stratification Insights$

Hematology-Oncology news Oncology

Enhanced Salvage Therapy in Relapsed/Refractory AML: Venetoclax Plus High-Dose Cytarabine and Mitoxantrone Shows Promising Outcomes and Risk Stratification Insights

By MedXY 08/24/2026

A multicenter real-world study demonstrates that combining venetoclax with high-dose cytarabine and mitoxantrone significantly improves remission and survival rates in relapsed/refractory AML, with validated risk factors guiding prognostication.

Hematology-Oncology news

Transcription Factor NFE2: A Crucial Regulator of Redox Balance and Chemotherapy Resistance in Acute Myeloid Leukemia

By MedXY 08/24/2026

NFE2 drives leukemic transformation through redox regulation, modulating glutathione homeostasis and detoxification pathways, and confers chemotherapy resistance in AML. Targeting NFE2 may enhance therapeutic efficacy and improve patient outcomes.

Hematology-Oncology news

Engineering High-Avidity Cathepsin-G-Specific CAR T Cells: A Promising Therapeutic Strategy for Acute Myeloid Leukemia

By MedXY 08/23/2026

This article reviews the development of high-avidity cathepsin-G-specific CAR T cells engineered with enhanced functional features to selectively target acute myeloid leukemia without hematopoietic toxicity, highlighting their preclinical efficacy, mechanistic insights, and clinical potential.

Hematology-Oncology news Oncology

Relapse and Survival Benchmarks in Non-Transplanted AML Patients Achieving First Complete Remission

By MedXY 08/17/2026

A retrospective study delineates relapse risks and survival outcomes in adult acute myeloid leukemia patients who achieve first complete remission without undergoing allogeneic stem cell transplantation, highlighting venetoclax’s role in reducing relapse.

Hematology-Oncology news

Unraveling the Blockade: How Mutant IDH1 Impairs Neutrophil Differentiation in Preleukemic Hematopoiesis

By MedXY 08/17/2026

Mutant IDH1 in acute myeloid leukemia causes a reversible block in neutrophil differentiation by repressing myeloid progenitor transcriptional programs, highlighting a preleukemic defect with therapeutic implications.

Hematology-Oncology news

Comparing Total Body Irradiation and Chemotherapy Conditioning in Haploidentical Transplants for AML Patients in First Remission: Insights from the EBMT Registry

By MedXY 08/10/2026

This study evaluates survival and relapse outcomes of total body irradiation versus chemotherapy conditioning regimens in haploidentical hematopoietic cell transplantation for adult AML patients in first remission, revealing no clear survival advantage with TBI.

Hematology-Oncology news

Unexpected Prognostic Significance of FLT3-ITD Microclones in Young Adults with Acute Myeloid Leukemia Undergoing Intensive Chemotherapy

By MedXY 08/05/2026

Low-level FLT3-ITD microclones, detected via NGS in young adults with AML, independently increase relapse risk comparable to macroclones, challenging current risk stratification and underscoring the need to integrate advanced genetic testing in clinical practice.

Clinical Updates Hematology-Oncology news

G3BP2-Mediated Venetoclax Resistance via ELF1-Driven MCL1 Transcription in Acute Myeloid Leukemia: Mechanisms and Therapeutic Implications

By MedXY 07/24/2026

This review synthesizes evidence on the role of RNA-binding protein G3BP2 in conferring venetoclax resistance in AML through stabilizing ELF1 mRNA and upregulating MCL1 transcription, highlighting novel therapeutic avenues combining G3BP2 inhibition with venetoclax.

Hematology-Oncology news

Measurable Residual Disease as a Prognostic Biomarker in Frontline Azacitidine and Venetoclax-Treated AML: Insights from the French VENAURA Registry

By MedXY 07/20/2026

In AML patients receiving frontline azacitidine and venetoclax, achieving measurable residual disease negativity strongly predicts longer survival and lower relapse rates, overriding baseline risk factors, as shown in the French VENAURA registry.

Hematology-Oncology news Oncology

EIF4A3-Driven Nonsense-Mediated Decay: A Novel Regulatory Axis Modulating AML1-ETO9a Dosage and Clinical Outcomes in t(8;21) Acute Myeloid Leukemia

By MedXY 07/17/2026

This review highlights how EIF4A3-dependent nonsense-mediated mRNA decay selectively regulates the oncogenic AML1-ETO9a isoform in t(8;21) AML, influencing leukemic cell proliferation, chemosensitivity, and patient survival through an isoform-specific dosage checkpoint.

$CD7-Directed CAR-T Cell Therapy in Relapsed/Refractory CD7-Positive Acute Myeloid Leukemia: Clinical Advances and Future Perspectives$

Clinical Updates news

CD7-Directed CAR-T Cell Therapy in Relapsed/Refractory CD7-Positive Acute Myeloid Leukemia: Clinical Advances and Future Perspectives

By MedXY 07/13/2026

This review synthesizes recent phase I trial data on CD7 CAR-T therapies in relapsed/refractory AML, highlighting promising safety, high response rates, challenges with antigen loss relapse, and avenues for future research.

Hematology-Oncology news

Decoding Clonal Evolution and Immunophenotype in NPM1-Mutated AML through Single-Cell Multiomics

By MedXY 07/02/2026

Single-cell multiomic analysis reveals how genotype-immunophenotype relationships shape clonal evolution in NPM1-mutated acute myeloid leukemia, highlighting implications for prognosis and therapy response.

Hematology-Oncology news

Enhancing Acute Myeloid Leukemia Treatment: Dual CDK2 and CDK4/6 Inhibition Targets Cell Cycle and Rb/E2F Signaling

By MedXY 06/25/2026

Dual inhibition of CDK2 and CDK4/6 demonstrates synergistic anti-leukemic effects in AML by suppressing the Rb/E2F axis, offering a promising therapeutic strategy to improve outcomes in this challenging hematologic malignancy.

Hematology-Oncology news Pathology & Lab Medicine/Bệnh học

Next-Generation Sequencing MRD Detection Predicts Outcomes in AML Patients Undergoing Allogeneic Stem Cell Transplantation

By MedXY 05/30/2026

A low-cost NGS-based MRD test detected hidden AML cells before transplant and strongly predicted worse survival after allogeneic stem cell transplantation.

Hematology-Oncology news Oncology

Molecular Profiling Refines Relapse Risk After Allogeneic Transplant in First-Remission Acute Myeloid Leukemia

By MedXY 05/11/2026

A PETHEMA registry study shows that specific mutations, especially DNMT3A, SF3B1, TP53, and WT1, meaningfully refine relapse-free survival after allo-HSCT in first-remission AML beyond ELN risk groups.

Hematology-Oncology news

Targeting the Sugar Coat: Oncofetal Chondroitin Sulfate Emerges as a Precision ADC Target in AML

By MedXY 03/27/2026

Researchers have identified oncofetal chondroitin sulfate (ofCS) as a novel target for antibody-drug conjugates in AML. Unlike traditional targets, ofCS is absent in healthy tissues, potentially reducing hematotoxicity and expanding treatment options for patients ineligible for intensive chemotherapy.